315 Results for "

C-myc

" in MedChemExpress (MCE) Product Catalog:
Products (315)

315 Results for "C-myc" in MCE Product Catalog:

  • Targets Recommended:
93
93 Publications Verification
Cat. No.: HY-K0206

MCE Anti-c-Myc Magnetic Beads are used for immunoprecipitation (IP) of specific c-Myc-tagged proteins expressed in bacterial and mammalian cells and in vitro expression systems. The 1 mL is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

loading...
    loading...
62
62 Cited Publications
Cat. No.: HY-12702
CAS No.: 403811-55-2
Purity:  99.49%
Target:  

c-Myc Autophagy

Research Areas:  

Cancer

10058-F4 is a c-Myc inhibitor that prevents c-Myc-Max dimerization and transactivation of c-Myc target gene expression.
loading...
    loading...
52
52 Cited Publications
Cat. No.: HY-15947
CAS No.: 1453848-26-4
Synonyms: GDC-0994
Research Areas:  

Cancer

Ravoxertinib (GDC-0994) is an orally active ERK1/2 inhibitor. Ravoxertinib inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma .
loading...
    loading...
52
52 Cited Publications
Cat. No.: HY-15947A
CAS No.: 2070009-58-2
Synonyms: GDC-0994 hydrochloride
Research Areas:  

Cancer

Ravoxertinib hydrochloride (GDC-0994 hydrochloride) is an orally active ERK1/2 inhibitor. Ravoxertinib hydrochloride inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib hydrochloride decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib hydrochloride can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma .
loading...
    loading...
37
37 Cited Publications
Cat. No.: HY-16954
CAS No.: 1818885-28-7
ARV-825 is a BET protein PROTAC degrader that recruits cereblon, and it targets BRD2, BRD3, and BRD4 for degradation via the ubiquitin-proteasome pathway. ARV-825 downregulates c-MYC, PLK1, MYCN, CDK4/6, JAK2, pSTAT3/5, PIM1, and Bcl-xL, upregulates p21 and p27, and modulates H3K27Ac-mediated transcription, the G2/M checkpoint, the Wnt/β-catenin pathway, and amino acid transport pathways. ARV-825 induces G1 phase cell cycle arrest, caspase 3/PARP-mediated apoptosis, DNA damage, and reactive oxygen species (ROS) production, reduces mitochondrial respiration, and simultaneously inhibits cell proliferation, clonogenic growth, and cell migration. ARV-825 is used in research on gastric cancer, leukemia, neuroblastoma, and cholangiocarcinoma .
loading...
    loading...
30
30 Cited Publications
Cat. No.: HY-100972
CAS No.: 1949837-12-0
Purity:  98.87%
ARV-771 is a BET PROTAC degrader, with Kd values of 34, 4.7, 8.3, 7.6, 9.6 and 7.6 nM against BRD2 (1), BRD2 (2), BRD3 (1), BRD3 (2), BRD4 (1) and BRD4 (2) , respectively. ARV-771 inhibits the transcription of AR/AR-v7 and its downstream target genes. By degrading BRD4 protein, ARV-771 enhances the sensitivity of prostate cancer cells to ferroptosis, suppresses cancer cell viability, and induces apoptosis. ARV-771 downregulates the levels of BRD4, c-MYC and AR-V7 in tumor tissues and inhibits tumor tissue growth. ARV-771 can be used in prostate cancer-related research .
loading...
    loading...
23
23 Cited Publications
Cat. No.: HY-16291
CAS No.: 916151-99-0
Synonyms: LOR-253; LT-253
Target:  

c-Myc KLF Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

APTO-253 (LOR-253) is a small molecule that inhibits c-Myc expression, stabilizes G-quadruplex DNA, and induces cell cycle arrest and apoptosis in acute myeloid leukemia cells. APTO-253 mediates anticancer activity through induction of the Krüppel-like factor 4 (KLF4) tumor suppressor . APTO-253 has antiarthritic activity .
loading...
    loading...
22
22 Cited Publications
Cat. No.: HY-107738
CAS No.: 95975-55-6
Purity:  99.81%
Synonyms: Z/E-Guggulsterone
Guggulsterone is a plant sterol derived from the gum resin of the tree Commiphora wightii. Guggulsterone inhibits the growth of a wide variety of tumor cells and induces apoptosis through down regulation of antiapoptotic gene products (IAP1, xIAP, Bfl-1/A1, Bcl-2, cFLIP and survivin), modulation of cell cycle proteins (cyclin D1 and c-Myc), activation of caspases and JNK, inhibition of Akt . Guggulsterone, a farnesoid X receptor (FXR) antagonist, with IC50s of 24.06 μM and 39.05 μM for (-)-(E)-Guggulsterone (HY-N7781) and (Z)-Guggulsterone (HY-110066), respectively .
loading...
    loading...
19
19 Cited Publications
Cat. No.: HY-17381A
CAS No.: 58957-92-9
Synonyms: 4-Demethoxydaunorubicin
Idarubicin is an orally active and potent anthracycline antileukemic agent. Idarubicin inhibits the topoisomerase II interfering with the replication of DNA and RNA transcription. Idarubicin shows induction of DNA damage. Idarubicin inhibits DNA synthesis and of c-myc expression. Idarubicin inhibits the growth of bacteria and yeasts .
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-13241
CAS No.: 862507-23-1
Purity:  99.94%
Synonyms: LY2228820 dimesylate
Research Areas:  

Inflammation/Immunology Cancer

Ralimetinib dimesylate (LY2228820 dimesylate) is a selective, ATP-competitive inhibitor of p38 MAPK α/β with IC50s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38a MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc.
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-111784
CAS No.: 2222941-37-7
Purity:  99.94%
Synonyms: CCS1477
Inobrodib (CCS1477) is an orally active, potent, and selective inhibitor of the p300/CBP bromodomain. Inobrodib binds to p300 and CBP with Kd values of 1.3 and 1.7 nM, respectively, and with 170/130-fold selectivity compared with BRD4 with a Kd of 222 nM. CCS1477 inhibits cell proliferation in prostate cancer cell lines and decreases androgen receptor (AR)- and C-MYC-regulated gene expression .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-15594A
CAS No.: 929895-45-4
Purity:  98.99%
Synonyms: Phen-DC3 Triflate
Phen-DC3 Trifluoromethanesulfonate is a bisquinolinium G-quadruplex (G4) ligand. Phen-DC3 Trifluoromethanesulfonate selectively binds to and stabilizes the hybrid quadruplex-duplex hybrid (QDH) derived from the PIM1 promoter. Phen-DC3 Trifluoromethanesulfonate also binds to the c-myc promoter Pu24T G4 via extensive π-stacking, and induces polymerase stalling at α-synuclein DNA and RNA G4 sequences. Phen-DC3 Trifluoromethanesulfonate downregulates LPS (HY-D1056)-induced TNFRSF21, RIPK3 and p-MLKL in VECs, and ameliorates CLP-induced pulmonary vascular leakage in septic rats. Phen-DC3 Trifluoromethanesulfonate can be used in studies related to neurodegenerative diseases and sepsis-associated vascular injury .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-136144
CAS No.: 1391934-98-7
Purity:  98.46%
Research Areas:  

Cancer

FIDAS-5 is a potent and orally active methionine S-adenosyltransferase 2A (MAT2A) inhibitor with an IC50 of 2.1 μM. FIDAS-5 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-5 has anticancer activities .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-145669
CAS No.: 113411-17-9
Purity:  99.84%
Target:  

Wnt CDK GSK-3

Research Areas:  

Infection Cancer

DIF-3 is an orally active anticancer agent. DIF-3 reduces the expression levels of cyclin D1 and c-Myc by facilitating their degradation via activation of GSK-3β. DIF-3 inhibits Wnt/β-catenin signaling pathway-related proteins in cells. DIF-3 induces reactive oxygen species (ROS) and autophagy. DIF suppresses the growth of Trypanosoma. cruzi in HT1080 cells. DIF-3 exerts antitumor effects both in vitro and in vivo .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-P80626
Synonyms: myc; BHLHE39; myc proto-oncogene protein; Class E basic helix-loop-helix protein 39; bHLHe39; Proto-oncogene c-myc; Transcription factor p64

Host:  

Rabbit

Application:  

WB, ICC/IF, IP

Reactivity:  

Human, Mouse, Rat

loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-10285
CAS No.: 361442-04-8
Purity:  99.96%
Synonyms: BMS-477118
Target:  

Dipeptidyl Peptidase

Research Areas:  

Metabolic Disease

Saxagliptin (BMS-477118) is a potent, selective, reversible, competitive and orally active dipeptidyl peptidase-4 (DPP-4) (Ki = 0.6-1.3 nM) inhibitor. Saxagliptin has the peotential for type 2 diabetes mellitus research .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-10285A
CAS No.: 945667-22-1
Purity:  98.13%
Synonyms: BMS-477118 hydrate
Target:  

Dipeptidyl Peptidase

Research Areas:  

Metabolic Disease

Saxagliptin hydrate (BMS-477118 hydrate) is a potent, selective, reversible, competitive and orally active dipeptidyl peptidase-4 (DPP-4) (Ki = 0.6-1.3 nM) inhibitor. Saxagliptin hydrate has the peotential for type 2 diabetes mellitus research .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-16448
CAS No.: 709031-78-7
Synonyms: BMS-477118 hydrochloride
Target:  

Dipeptidyl Peptidase

Research Areas:  

Metabolic Disease

Saxagliptin hydrochloride (BMS-477118 hydrochloride) is a potent, selective, reversible, competitive and orally active dipeptidyl peptidase-4 (DPP-4) (Ki = 0.6-1.3 nM) inhibitor. Saxagliptin hydrochloride has the peotential for type 2 diabetes mellitus research .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-123844
CAS No.: 1883863-52-2
Purity:  99.94%
dBET57 is a potent and selective BRD4BD1 PROTAC degrader with a DC50 of approximately 500 nM. dBET57 forms a ternary complex with CRL4 CRBN and BRD4BD1, induces the ubiquitination and degradation of BRD4, and indirectly inhibits the transcription of MYCN, c-Myc and PD-L1, ultimately leading to cell cycle arrest and apoptosis. dBET57 can be used in related research on neuroblastoma, non-small cell lung cancer and colorectal cancer .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-100669
CAS No.: 944547-46-0
Purity:  98.11%
Target:  

c-Myc Autophagy

Research Areas:  

Cancer

Mycro 3 is an orally active, potent and selective inhibitor of Myc-associated factor X (MAX) dimerization. Mycro 3 also inhibit DNA binding of c-Myc . Mycro 3 could be used for the research of pancreatic cancer .
loading...
    loading...